Education
About Us
Working with TipRanks
Follow Us
TherapeuticsMD (TXMD)
NASDAQ:TXMD
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.72 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$26.16M
Enterprise Value$25.53M
Total Cash (Recent Filing)$7.12M
Total Debt (Recent Filing)$6.48M
Price to Earnings (P/E)86.6
Beta1.34
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.36
Price to Sales (P/S)5.63
P/FCF Ratio13.55
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue9.13
Enterprise Value/Gross Profit9.13
Enterprise Value/Ebitda-26.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Licensing-based Business ModelA licensing-first model reduces fixed commercial costs and capital intensity by shifting manufacturing, marketing and distribution to partners. Over months this supports scalable, less capital-dependent revenue (upfronts, milestones, royalties), improving long-term cash convertibility if deals continue.
Improved Cash GenerationTurning operating and free cash flow positive marks a material structural improvement from prior years. Consistent FCF provides runway for licensing negotiations, potential M&A evaluation, and lowers reliance on external financing, strengthening resilience across the next several quarters.
Manageable LeverageLow absolute debt and a modest debt-to-equity ratio give the company balance-sheet flexibility to fund strategic alternatives or weather revenue variability. This reduced leverage lowers interest burden and preserves capacity for targeted investments or licensing transactions over the medium term.
Bears Say
Weak Operating ProfitabilityDeeply negative EBIT and EBITDA margins signal the core business has not yet generated sustainable operating earnings. Absent durable operating improvements or steady recurring royalties, profitability weakness risks recurring losses and constrains reinvestment and long-term shareholder returns.
Dependence On Commercialization PartnersRelying on licensees for manufacturing, marketing and sales transfers execution risk away from the company. Long-term revenue and royalty streams can be uneven and outside management's direct control, limiting predictability of cash flow and making growth contingent on partner performance.
Limited Cash Coverage Vs DebtA low operating cash flow to debt coverage ratio indicates limited internal cushion to service obligations if revenues slip. This constrains strategic flexibility and raises reliance on external financing or new licensing deals until operating cash generation sustainably increases.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.72 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $26.16M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Mar 27, 2026 which is in 25 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on Nov 12, 2025. The company reported $0.013 earnings per share for the quarter, beating the consensus estimate of N/A by $0.013.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.013 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.05% Mutual Funds
20.77% Other Institutional Investors
70.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---